Botanical Therapy for Acute Viral Respiratory Infections

This Phase 1 study will evaluate the feasibility and safety of implementing a host pathologic state-directed botanical therapeutic platform in adults with acute viral respiratory infections. The platform, called Dynamic Pathology-Based Therapy (DPBT), uses a predefined clinical algorithm to identify participants' pathological states and select the corresponding botanical formulation module or combination of modules. Approximately 30 adults aged 18 to 80 will participate in this prospective, single-group, open-label study. All participants will receive the assigned DPBT intervention in addition to medically appropriate standard care. Treatment will generally continue for 7 days and may be extended through Day 10 if predefined pathological states persist. Study assessments will examine protocol implementation, recruitment and retention, adherence, treatment tolerability, adverse events, changes in symptoms and recovery, and exploratory changes in viral detection through Day 12.

Inclusion Criteria * Adults aged 18-80 years. * Presence of an acute viral respiratory infection or clinical presentation consistent with an acute viral respiratory infection. * Onset of acute respiratory symptoms within a predefined period before enrollment. * Presence of one or more predefined pathological states eligible for treatment according to the DPBT clinical algorithm. * Able and willing to comply with study treatment, clinical assessments, and viral testing. * Able to understand the study requirements and provide written informed consent. Exclusion Criteria * Severe or life-threatening illness requiring immediate hospitalization or emergency medical treatment at enrollment. * Known allergy, hypersensitivity, or clinically significant intolerance to any ingredient in the botanical formulations that may be administered. * Pregnancy or breastfeeding. * Significant medical condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study outcomes. * Current participation in another interventional clinical trial that could interfere with this study. * Unable or unwilling to comply with study procedures or provide informed consent.